Cobo-Ibáñez T, Martín-Mola E
Hospital Universitario La Paz, Servicio de Reumatología, Paseo de la Castellana 261, 28046 Madrid, Spain.
Expert Opin Pharmacother. 2007 Jun;8(9):1373-97. doi: 10.1517/14656566.8.9.1373.
Etanercept is a dimeric fusion protein based on the p75 TNF-alpha receptor. It binds to TNF-alpha and blocks its biologic activity. In randomized, double-blind, placebo-controlled trials, etanercept has therapeutic activity in rheumatoid arthritis, psoriatic arthritis, polyarticular-course juvenile idiopathic arthritis and ankylosing spondylitis. Etanercept improves joint inflammation, physical function and slows/halts structural damage, especially when combined with methotrexate. A sustained response is observed in a substantial percentage of patients. Although some safety issues should be considered before starting etanercept treatment, in general terms, etanercept is a well tolerated drug with an acceptable safety profile. The use of any TNF-alpha antagonist must be in agreement with the National Recommendations for Biologic Therapy, and in difficult clinical situations, a balance between risk/benefit needs to be obtained.
依那西普是一种基于p75肿瘤坏死因子-α受体的二聚体融合蛋白。它与肿瘤坏死因子-α结合并阻断其生物活性。在随机、双盲、安慰剂对照试验中，依那西普对类风湿性关节炎、银屑病关节炎、多关节型幼年特发性关节炎和强直性脊柱炎具有治疗活性。依那西普可改善关节炎症、身体功能并减缓/阻止结构损伤，尤其是与甲氨蝶呤联合使用时。相当比例的患者观察到持续缓解。尽管在开始依那西普治疗前应考虑一些安全问题，但总体而言，依那西普是一种耐受性良好且安全性可接受的药物。任何肿瘤坏死因子-α拮抗剂的使用都必须符合国家生物治疗建议，在困难的临床情况下，需要权衡风险/获益。
